263 related articles for article (PubMed ID: 34842351)
21. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
[TBL] [Abstract][Full Text] [Related]
22. A case of bilateral methotrexate-associated diffuse large B-cell lymphomas of the breasts with unique clinical presentation and outcome.
Tomita M; Oura S; Nishiguchi H; Makimoto S
Breast Cancer; 2020 Sep; 27(5):1038-1043. PubMed ID: 32361905
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.
Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.
Ejima-Yamada K; Oshiro Y; Okamura S; Fujisaki T; Mihashi Y; Tamura K; Fukushige T; Kojima M; Shibuya K; Takeshita M
Virchows Arch; 2017 Feb; 470(2):205-215. PubMed ID: 27864689
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate-Related Lymphoproliferative Disorder Presenting with Severe Swelling of the Elbow Joint: A Case Report.
Hatano T; Ohishi M; Yoshimoto G; Yamauchi M; Maekawa A; Yamamoto H; Oda Y; Endo M; Bekki H; Matsunobu T; Nakashima Y; Okazaki K; Fukushi JI; Oyamada A; Iwamoto Y
JBJS Case Connect; 2017; 7(3):e65. PubMed ID: 29252894
[TBL] [Abstract][Full Text] [Related]
28. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
30. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.
Satou A; Nakamura S
Cancer Med; 2021 Oct; 10(19):6777-6785. PubMed ID: 34387382
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
[TBL] [Abstract][Full Text] [Related]
32. Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases.
Satou A; Tabata T; Suzuki Y; Sato Y; Tahara I; Mochizuki K; Oishi N; Takahara T; Yoshino T; Tsuzuki T; Nakamura S
Virchows Arch; 2021 May; 478(5):969-976. PubMed ID: 33169195
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate-related lymphoproliferative disorder of the lumbar spine origin presenting with severe low-back pain: case report.
Kikuchi N; Uesugi M; Koda M; Shimizu T; Murakami K; Kono M; Tanaka H; Yamazaki M
J Neurosurg Spine; 2018 Nov; 29(5):545-548. PubMed ID: 30168781
[TBL] [Abstract][Full Text] [Related]
35. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient.
Tanaka K; Kuboki M; Koi S; Toyota S
Intern Med; 2020 Mar; 59(6):829-833. PubMed ID: 31761888
[TBL] [Abstract][Full Text] [Related]
37. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
Kobayashi Y; Kimura K; Fujitsu Y; Shinkawa K; Muta H; Sonoda KH
Jpn J Ophthalmol; 2016 May; 60(3):212-8. PubMed ID: 27018050
[TBL] [Abstract][Full Text] [Related]
39. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]